Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%
Jiangzhong pharmaceutical announced that according to the company's preliminary prediction, the total operating revenue in the first quarter of 2022 is expected to be about 890 million yuan, an increase of about 30% year-on-year; The net profit attributable to the parent company is expected to be about 180 million yuan, with a year-on-year increase of about 11%.
This text is a result of machine translation.
Related companies：
Briefing Mar 21, 2025 05:14 PM
· Technology
Shanghai to Launch Its First Direct Passenger Flight Route to a Central Asian Country in May
In-depth
Financials, Communication
Chinese Education Goes Global: Capturing a Trillion-Dollar Market
A TikTok filter challenge called "Mandarin Fruit Voices" has gone viral. Essentially a straightforward Mandarin learning game with crude animations, minimalist gameplay, and fruit-based pronunciation exercises drawn from early childhood education materials, it has nonetheless captivated international users. For those who once struggled with English, the long-held dream of a world united by Chinese now appears increasingly within reach.
Mar 27, 2025 06:55 PM
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Technology
WeRide Partners with Uber and Dubai's RTA to Launch Robotaxi Service
Apr 08, 2025 01:21 PM
Briefing Nov 01, 2021 09:43 AM
· Technology
Semiconductor plate opened stronger
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
Briefing Aug 02, 2021 06:01 PM
· Technology
Shennan circuit: it is proposed to raise no more than 2.55 billion yuan
See more
Read next
Insight
In-depth
Automotive · Analysis
Chinese Automakers Break into a €10 Billion Market in Europe
Apr 11, 2025 09:57 PM
Insight
In-depth
Automotive · Analysis
Tariff Escalation Through the Lens of Geopolitical Economy
Apr 11, 2025 12:32 PM
Insight
In-depth
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
Apr 07, 2025 03:46 PM
Insight
In-depth
